Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles Francesca PistollatoSusanne Bremer-HoffmannMaurizio Battino Review 16 August 2015 Pages: 1 - 16
Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review Norbertus A. IpenburgKoos KooleStefan M. Willems Review Article Open access 27 June 2015 Pages: 17 - 27
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition Katrin LiffersKatarina KolbeAlexander Schulte Original Research 03 June 2015 Pages: 29 - 40
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis Gaetan Des GuetzThierry LandreJean-François Morere Original Research 20 June 2015 Pages: 41 - 47
RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials Jin LiuZhixin ShengGuixin Li Original Research Article 25 July 2015 Pages: 49 - 58
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma N. KramkimelA. Thomas-SchoemannB. Blanchet Original Research 25 July 2015 Pages: 59 - 69
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study Christelle de la FouchardiereNadia OussaidFrançoise Borson-Chazot Original Research Article 20 August 2015 Pages: 71 - 82
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort Magali RouyerDenis Smithon behalf of the ETNA study group Original Research 23 August 2015 Pages: 83 - 92
Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients Kazuhiro YamamotoKazuaki ShinomiyaMidori Hirai Original Research Article 25 August 2015 Pages: 93 - 99
HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases Haruhiko DozonoShintaro YanazumeHiroshi Maeda Day-to-Day Practice 22 July 2015 Pages: 101 - 106
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma Sarah L. Greig Adis Drug Evaluation 29 January 2016 Pages: 107 - 114
Lenvatinib: A Review in Refractory Thyroid Cancer James E. Frampton Adis Drug Evaluation 12 February 2016 Pages: 115 - 122
Comment on: “Regorafenib: Start Low and Go Slow” Christelle de la Fouchardière Letter to the Editor 04 December 2015 Pages: 123 - 125
Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow” Samer TabchiMarwan Ghosn Letter to the Editor 09 December 2015 Pages: 127 - 128